Navigation Links
New Treatment For Obstructive Sleep Apnea Now Available In Canada
Date:11/19/2012

SAN JOSE, Calif. and TORONTO, Nov. 19, 2012 /PRNewswire/ -- Ventus Medical is pleased to announce the introduction of its proprietary Provent® Sleep Apnea Therapy into Canada. Provent Therapy is an innovative, non-invasive treatment for obstructive sleep apnea (OSA). Provent Therapy is now available in the province of Ontario and will be available throughout Canada by June 2013. ioSleep, Inc. is the strategic distribution partner of Provent Therapy in Canada.

(Photo: http://photos.prnewswire.com/prnh/20121119/SF15670)

(Logo: http://photos.prnewswire.com/prnh/20120712/LA37941LOGO)

There is growing demand for clinically proven sleep apnea treatments and the introduction of Provent represents a scientifically validated, innovative and user-friendly approach. Provent works across mild, moderate, and severe OSA and utilizes nasal expiratory positive airway pressure (EPAP) to keep a patient's airway open during sleep.

"According to the Public Health Agency of Canada over 1 in 4 Canadian adults are at high risk of having OSA.  OSA is suspected in patients who are loud snorers, excessively sleepy, obese and hypertensive," said Dr. John Fleetham, Professor of Medicine at the University of British Columbia. "OSA is increasingly being recognised in Canadian patients.  CPAP (continuous positive airway pressure) is the primary treatment for OSA, however not all patients can tolerate it as a long term treatment." Dr. Fleetham further comments, "I welcome new validated treatment alternatives for OSA such as Provent Sleep Apnea Therapy."

"We believe clinically-proven Provent Therapy offers a unique and convenient alternative to CPAP treatment for the large number of people in Canada currently affected by OSA," said Philip Westbrook, M.D., chief medical officer of Ventus Medical. "Prove
'/>"/>

SOURCE Ventus Medical
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
3. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
4. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
5. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
6. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
7. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
8. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
9. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
10. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... LYNBROOK, N.Y. , Sept. 19, 2014  BioSpecifics Technologies ... first in class collagenase-based products marketed as XIAFLEX ® ... announced today that BioSpecifics, President, Tom Wegman , will ... BioCentury NewsMakers in the Biotech Industry Conference. ... at 3:00 p.m. EDT at the Millennium Broadway Hotel in ...
(Date:9/19/2014)... , Sept. 19, 2014 Intarcia Therapeutics, ... clinical data for its lead candidate ITCA 650 (continuous ... with high baseline HbA1c levels at the 50 th ... Study of Diabetes (EASD). Data from the open-label, phase ... of blood sugar in patients with poorly controlled type ...
(Date:9/19/2014)... 19, 2014  PCI is pleased to announce ... is a leading provider of Clinical Trial Services ... Wales in the ... expands PCI,s presence in the UK/EU to support ... packaging, storage and distribution capacity, as well as ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6
... NEW YORK, Jan. 10, 2012  ( http://www.myprgenie.com/  ) ... Americans 10 years ago and ask them where they found ... their current healthcare provider in their insurance plan directory or ... that is not the case.  Eighty percent of all U.S. ...
... uVera Diagnostics has introduced the CR3 Keyless Split Sample Cup ... cup provides several state-of-the-art features not available together in any ... to the drug testing industry," said Rick Nee, president of ... of use for both genders. The unique patented device is ...
Cached Medicine Technology:Castle Connolly Makes Finding the Best Healthcare from Top Doctors Even Easier 2uVera Diagnostics Offers New Drug Screening Product 2
(Date:9/19/2014)... (PRWEB) September 20, 2014 As summer vacations ... DMD in Queens, NY now reminds area patients about the ... 80% of our population affected by gum disease, there is ... , For over 20 years Dr. Krishnan has treated patients ... office location. “Most patients that come in due to common ...
(Date:9/19/2014)... Majidi, M.D., a second-year resident in the Department ... of Medicine and Health Sciences, received at $154K ... the presence of diffuse brain swelling and injury ... to epidemiological studies, intracerebral hemorrhage accounts for less ... the least treatable form of stroke, with the ...
(Date:9/19/2014)... BCC Research reveals in its new ... , the global market for human antifungal therapeutics is ... with a five-year compound annual growth rate (CAGR) of ... a steady 3.8% CAGR. , Given the current world ... with the incidence of increasing mortality and the severity ...
(Date:9/19/2014)... Dallas, Texas (PRWEB) September 19, 2014 ... blocking the physiologic actions of leukotriene D4 (LTD4). LTD4 ... released from a variety of cells, including mast cells ... CysLT receptors. Several studies have determined that there are ... of asthmatics compared with non-asthmatic individuals. The production of ...
(Date:9/19/2014)... San Jose, California (PRWEB) September 19, 2014 ... agents, an integral part of the medical imaging market, ... organs. Effervescent technology developments over the past three decades ... medical diagnostics. From barium and iodine based agents used ... as gold nanoparticles and radiopharmaceuticals, imaging agents have witnessed ...
Breaking Medicine News(10 mins):Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 3Health News:GW researcher receives grant to study brain swelling following bleeding in the brain 2Health News:Global Market for Human Antifungal Therapeutics to Reach Nearly $13.9 Billion in 2018; Over-The-Counter (OTC) Segment Growing At 3.8% CAGR 2Health News:Global Market for Human Antifungal Therapeutics to Reach Nearly $13.9 Billion in 2018; Over-The-Counter (OTC) Segment Growing At 3.8% CAGR 3Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 2Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 3Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 4Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 2Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 3Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 4
... Aug. 13 As reported in publications and news,outlets ... "buck" teeth was replaced at the summer games opening ... the decision spawned,disbelief around the globe, sadly, the phenomenon ... of their teeth is nothing new., In a ...
... donations for breast cancer,research/programs, DETROIT, Aug. 13 ... part to end cancer, as well as honor the ... goal of walking 18,marathons in 18 days -- The ... cancer research and programs at the Barbara Ann Karmanos ...
... 3 new reports raise question of how long a heart ... 13 (HealthDay News) -- Three new reports challenge current guidelines ... taking a heart from an infant organ donor. , There,s ... no question that there aren,t enough donor organs to save ...
... Weiner Says Calls for,Privatization and ,Reform, are Granny-on-Your-Own, ... WASHINGTON, Aug. 13 On Social Security,s,73rd Anniversary ... of Staff,Robert Weiner is saying, "Calls to ,reform, ... Street,giveaway which would turn Social Security from a ...
... Held Thursday, August 14, 2008 at 9:00 a.m. Eastern ... ... Alseres,Pharmaceuticals, Inc. (Nasdaq: ALSE ) today reports operational and,financial results ... year 2008., (Logo: http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO ), "Alseres made solid ...
... -- Lotus,Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" ... Republic of China,("PRC"), today announced that it will ... on Monday, August 18, 2008 to discuss results ... Dr. Zhongyi Liu, Chairman and Chief Executive Officer ...
Cached Medicine News:Health News:Summer Games 'Swap' Raises Questions About Image, Oral Health 2Health News:More Than 400-mile Victory Walk to Conclude Aug. 14, at Campus Martius 2Health News:More Than 400-mile Victory Walk to Conclude Aug. 14, at Campus Martius 3Health News:Infant Heart Transplant Controversy Continues 2Health News:Infant Heart Transplant Controversy Continues 3Health News:Infant Heart Transplant Controversy Continues 4Health News:Social Security's 73rd Anniversary 2Health News:Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results 2Health News:Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results 3Health News:Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results 4Health News:Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results 5Health News:Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results 6Health News:Lotus Pharmaceuticals Announces Conference Call to Discuss Second Quarter 2008 Results 2
... Volks revolutionary MiniQuad, the DynaView 156 is ... of the retina extending to the ora ... patients. Featuring a minified housing and reduced ... revolutionizes retinopathy of prematurity surgery and is ...
... If you prefer a standard ... the Volk Iridectomy Lens. Its ... view you're used to but ... Volk's exclusive Double Aspheric design ...
... re-designed Super Macula® 2.2 offers extremely high ... fovea, while achieving an exceptionally wide 78° ... excellent choice for critical evaluation of the ... for detailed views of the macula and ...
... The Volk TransEquator is designed for ... diagnosis. Its unique optical design presents a ... an impressive wide-field view of the entire ... superior optics of this lens allows dynamic ...
Medicine Products: